Japan (2025, preliminary)
5,872.6
USD PPP per capita
-11.5 YoY
Government share
85.2
% of total (2023)
Private share
14.8
% of total (2023)
10-year change
+30.1
% since 2015

Data

Current Health Expenditure per Capita in Japan (2025) — source data. OECD.
Year USD PPP per capita YoY Change
2025 5,872.6 -0.2%
2024 5,884.2 -1.3%
2023 5,963.6 +1.5%
2022 5,878.2 +7.6%
2021 5,465 +12.5%
2020 4,858.5 +4.3%
2019 4,659.6 +2.6%
2018 4,543.3 +3.1%
2017 4,405.5 +2.6%
2016 4,292.2 -4.9%
2015 4,515.6 +4.3%
2014 4,328.4 +0.5%
2013 4,308.3 +8.5%
2012 3,970.8 +6.1%
2011 3,740.8 +18.0%
2010 3,169.2 +6.7%
2009 2,971.4 +6.2%
2008 2,799.2 +4.1%
2007 2,690 +5.0%
2006 2,561.2 +3.6%
2005 2,471.2 n/a

About this Dataset

Japan recorded 5,872.6 USD PPP per capita in current health expenditure in 2025, an OECD preliminary estimate down -11.5 from 2024's provisional figure of 5,884.2. Spending has grown in most years since 2005, when the series started at 2,471.2 USD PPP, though 2024 and 2025 mark a rare two-year pause after 2022's steep +413.2 rise.

Government and compulsory insurance schemes typically fund the large majority of this spending: in 2023 (the last finalized year) they covered about 85.2% of the total (5,079.0 USD PPP per capita), with voluntary insurance and household out-of-pocket payments making up the remaining 14.8% (884.6 USD PPP). That heavily government-financed split reflects Japan's universal statutory health insurance system and has stayed structurally similar over the past decade.

Compared with peer OECD economies, Japan's per-capita spending is likely running slightly above the OECD-38 average, roughly 3.6% over the unweighted average of about 5,754.7 USD PPP in 2023, and well ahead of South Korea (4,756.6 USD PPP) but far below the United States (13,932.6 USD PPP) that same year. The chart above shows the full 2005–2025 trend; the table below lists annual values with year-on-year changes.

Data sourced from the OECD System of Health Accounts (SHA) via SDMX REST API, filtered to Japan (JPN), total current health expenditure, converted to USD at purchasing power parity. The most recent year is flagged provisional or preliminary by the OECD and may be revised; a series break is flagged at 2011. The OECD-38 average is an unweighted mean computed across all current OECD member countries with reported data for the comparison year.

Frequently Asked Questions

This indicator tracks total current spending on health care per person in Japan, converted to USD at purchasing power parity (PPP) so levels are comparable across countries. It covers spending by government, private insurers, and households, published annually by the OECD under its System of Health Accounts (SHA). The most recent reading is 5,872.6 USD PPP in 2025 (preliminary).

The series runs through 2025, though that year is flagged as a preliminary OECD estimate and 2024 as provisional. The last fully finalized observation is 2023, at 5,963.6 USD PPP per capita. Figures are typically revised as national accounts are finalized, so the 2024 and 2025 values may shift in future OECD updates.

Japan's 5,963.6 USD PPP in 2023 (its last finalized year) sat roughly 3.6% above the unweighted OECD-38 average of about 5,754.7 USD PPP that year. It ran well above South Korea (4,756.6 USD PPP in 2023) but far below the United States (13,932.6 USD PPP in 2023), placing Japan among the higher-spending OECD economies that year.

In 2023, government and compulsory insurance schemes covered an estimated 5,079.0 USD PPP per capita (about 85.2% of the total), while voluntary insurance and household out-of-pocket payments accounted for roughly 884.6 USD PPP (about 14.8%). That split has stayed roughly stable over the past decade, up only slightly from about 84.3% government-financed in 2013, reflecting Japan's universal statutory health insurance system.

Per-capita spending has risen in most years since 2005, from 2,471.2 USD PPP that year to 5,872.6 USD PPP in 2025 — an increase of roughly 138% over two decades, and +30.1% just since 2015. The OECD flags a break in the series at 2011, when a methodology revision coincided with a jump from 3,169.2 to 3,740.8 USD PPP, so pre- and post-2011 figures are not fully comparable.